 |
Indication & Dosage |
| |
| |
| Oral |
| RECURRENT MISCARRIAGE |
| Adult:
250-500 mg wkly during the 1st half of pregnancy. |
| |
| Oral |
| AMENORRHOEA OR ABNORMAL UTERINE BLEEDING |
| Adult:
Single dose of 375 mg; may repeat at 4-wkly intervals if needed. After 4 days of desquamation, or if there is no bleeding within 21 days after admin of the drug, may initiate cyclic therapy that includes an oestrogen. For cyclic treatment (28-day cycle): Administer 20 mg of estradiol valerate on day 1, and on day 15, administer 250 mg of hydroxyprogesterone caproate and 5 mg of estradiol valerate. May repeat cyclic therapy at 4-wkly intervals as needed. |
| |
| Oral |
| PALLIATIVE TREATMENT OF ADVANCED, INOPERABLE ENDOMETRIAL CARCINOMA |
| Adult:
Usual dose: ≥1 g, may repeat once or more times wkly. Usual range: 1-7 g/wk. Discontinue treatment if relapse occurs or if the objective response is not achieved after 12 wk of treatment. |
|
| |
|
| Precautions |
Physical examination is advised prior to starting therapy. Hepatic impairment, mental depression. Monitor blood glucose in diabetic patients. Discontinue treatment upon signs of thromboembolic and thrombotic disorders. Discontinue treatment if unexplained, sudden or gradual, partial or complete loss of vision, protopsis, diplopia or papilledema, retinal vascular lesions or migraine occur. Caution when used in patients with conditions that might be worsened by fluid retention (e.g. asthma, seizure disorders, migraine, cardiac or renal dysfunction). |
| |
|
| Adverse Drug Reactions |
GI disturbances, increased appetite, wt gain or loss, oedema, acne, allergic skin rashes, urticaria, mental depression, discomfort in breast; cough, dyspnoea, circulatory disturbances. Pain at site of inj. |
| |
|
| Interactions |
Increased clearance when used with enzyme inducers e.g. carbamazepine and phenytoin. May inhibit metabolism of ciclosporin. |
| |
|
|
|
